Abstract
Nonalcoholic steatohepatitis (NASH) is an important indication for liver transplantation in many Western countries. Obesity and insulin resistance are the two most common risk factors for NASH, which can lead to recurrent NASH after liver transplantation. There is currently no approved therapy for NASH, and treatment is directed at risk factor modifcation and lifestyle changes. Betaine has been used for NASH, with mixed results, and may show promise in conjunction with other agents in clinical trials.
| Original language | English |
|---|---|
| Pages (from-to) | 3663-3664 |
| Number of pages | 2 |
| Journal | World Journal of Gastroenterology |
| Volume | 17 |
| Issue number | 32 |
| DOIs | |
| State | Published - Aug 28 2011 |
| Externally published | Yes |
Fingerprint
All Science Journal Classification (ASJC) codes
- Gastroenterology
Cite this
Betaine and nonalcoholic steatohepatitis : Back to the future? / Mukherjee, Sandeep.
In: World Journal of Gastroenterology, Vol. 17, No. 32, 28.08.2011, p. 3663-3664.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Betaine and nonalcoholic steatohepatitis
T2 - Back to the future?
AU - Mukherjee, Sandeep
PY - 2011/8/28
Y1 - 2011/8/28
N2 - Nonalcoholic steatohepatitis (NASH) is an important indication for liver transplantation in many Western countries. Obesity and insulin resistance are the two most common risk factors for NASH, which can lead to recurrent NASH after liver transplantation. There is currently no approved therapy for NASH, and treatment is directed at risk factor modifcation and lifestyle changes. Betaine has been used for NASH, with mixed results, and may show promise in conjunction with other agents in clinical trials.
AB - Nonalcoholic steatohepatitis (NASH) is an important indication for liver transplantation in many Western countries. Obesity and insulin resistance are the two most common risk factors for NASH, which can lead to recurrent NASH after liver transplantation. There is currently no approved therapy for NASH, and treatment is directed at risk factor modifcation and lifestyle changes. Betaine has been used for NASH, with mixed results, and may show promise in conjunction with other agents in clinical trials.
UR - http://www.scopus.com/inward/record.url?scp=80053910713&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=80053910713&partnerID=8YFLogxK
U2 - 10.3748/wjg.v17.i32.3663
DO - 10.3748/wjg.v17.i32.3663
M3 - Article
VL - 17
SP - 3663
EP - 3664
JO - World Journal of Gastroenterology
JF - World Journal of Gastroenterology
SN - 1007-9327
IS - 32
ER -